LATEST ONCOPRESCRIBE UPDATES
Late Breaking Abstract – ASCO 2026: CEL MoDs Significantly Extend Progression-Free Survival in Relapsed and Refractory Multiple Myeloma
Late Breaking Abstract – ASCO 2026: BREAKWATER Cohort 3 Expands First-Line Targeted Therapy Options for BRAF V600E-Mutant Metastatic Colorectal Cancer
Late Breaking Abstract – ASCO 2026: ctDNA-Guided Early Treatment Escalation Improves Outcomes in EGFR-Mutated Advanced NSCLC
FDA Approves WELIREG® with KEYTRUDA® for Adjuvant Treatment of Renal Cell Carcinoma
FDA Approves IBRANCE® with HER2 Targeted Therapy and Endocrine Therapy as Maintenance Treatment in HR-positive, HER2-positive Advanced Breast Cancer
Late Breaking Abstract – ASCO 2026: Ivonescimab Plus Chemotherapy Delivers Superior Overall Survival Benefit in Advanced Squamous NSCLC
Late Breaking Abstract – ASCO 2026: Evidence for Comprehensive PI3K/AKT/mTOR Pathway Inhibition in HR-Positive, HER2-Negative Advanced Breast Cancer
FDA Approves All-Oral Treatment for Newly Diagnosed Acute Myeloid Leukemia
NEW REGIMENS ADDED
VYLOY® with mFOLFOX 6 - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin), 5-FU and Leucovorin. Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveVYLOY® with CAPOX - for Gastric and GEJ cancer
VYLOY® (Zolbetuximab) with ELOXATIN® (Oxaliplatin) and XELODA® (Capecitabine). Regimen for Gastric and GastroEsophageal Junction adenocarcinoma whose tumors are Claudin (CLDN) 18.2 positiveENHERTU® - for Breast Cancer
Single Agent ENHERTU® (fam-trastuzumab deruxtecan-nxki) for Ultralow Metastatic Breast CancerOPDIVO® and YERVOY® with Limited Course Chemotherapy - for Non Small Cell Lung Cancer
OPDIVO® (Nivolumab) and YERVOY® (Ipilimumab) with 2 cycles of TAXOL® (Paclitaxel) and PARAPLATIN®(Carboplatin) - for advanced NSCLCJAYPIRCA® - for Mantle Cell Lymphoma
JAYPIRCA® (Pirtobrutinib) for Mantle Cell Lymphoma
Curbside Consultation
Bottom Ad
Advertisement
Subscribe
